Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to announce that ...

Positron emission tomography (PET) is an imaging modality to better understand the pathophysiology of a disease at molecular level and typically referred to as molecular imaging. It reveals the ...

Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce ...

Contemporary PET imaging has transitioned from a metabolic approach largely dominated by [¹⁸F]FDG to a multifaceted molecular platform encompassing a ...

PET scans can light up tumors in the body and help doctors determine if they are cancerous or benign (noncancerous). The results of a PET scan help guide medical decisions. A PET scan is a type of ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.

Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) on Wednesday announced “NovaScan Neuroimaging Clinics” as the new brand name ...

BUFFALO, N.Y. -- Using positron emission tomography (PET) scanning rather than other types of imaging as the first tool to diagnose heart-vessel blockages is more accurate, less invasive and saves ...